SCHEMBL3023200

SCHEMBL3023200

Cc1nc(Cl)c(C(=O)O)[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
MAPK1 P28482 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
KDM4E B2RXH2 2/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
PTPRB P23467 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TDP1 Q9NUW8 2/20 0.37
HSP90AA1 P07900 1/20 0.37
ESR2 Q92731 1/20 0.37
HPGD P15428 2/20 0.35
TSHR P16473 1/20 0.35
HCAR2 Q8TDS4 1/20 0.35
PDK2 Q15119 1/20 0.34
PIN1 Q13526 3/20 0.32
DHODH Q02127 2/20 0.32
CYP1A2 P05177 1/20 0.32
CASP1 P29466 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3641467 0.81 POLB (0.40) ALDH1A1PDK2
SCHEMBL21238631 0.77 KDM4E (0.39) ALDH1A1MAPK1SMN1; SMN2KDM4ECYP3A4
SCHEMBL3023228 0.77 HSP90AA1 (0.39) ALDH1A1MAPK1SMN1; SMN2KDM4ETDP1
SCHEMBL213561 0.76 PIN1 (0.48) ALDH1A1MAPK1KDM4ETDP1HSP90AA1
SCHEMBL3032708 0.74 GPR35 (0.37) ALDH1A1MAPK1SMN1; SMN2KDM4ECYP2C9
SCHEMBL3038885 0.74 KDM4E (0.36) ALDH1A1MAPK1SMN1; SMN2KDM4ECYP3A4
SCHEMBL3034374 0.74 GAA (0.37)
SCHEMBL4747475 0.74 IGF1R (0.37)
SCHEMBL3025482 0.71 GLA (0.36) KDM4ECYP3A4CYP2C9PTPRBHSD17B10
SCHEMBL8652103 0.71 GAA (0.43) ALDH1A1KDM4ETDP1HSP90AA1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US disclosed
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US disclosed
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US disclosed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US disclosed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US disclosed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US disclosed
EP-2166856-A1 CHEMICAL COMPOUNDS GlaxoSmithKline LLC (US) 2010-03-31 EP disclosed
WO-2008154271-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-18 WO disclosed
WO-2008154271-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216746-A1 CHEMICAL COMPOUNDS SAMHD1, POLRMT, NUDT1 ALDH1A1 348/4885MAPK1 2655/4885SMN1; SMN2 3196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.